Get healthy returns from these three healthcare stocks

Professional investor Paul Major of the BB Healthcare Trust highlights three of his favourite healthcare stocks.

As we look towards the post-coronavirus era, the predominant macroeconomic-investment theme is “reopening and recovery”. Investors have been flocking to pro-cyclical, inflation-sensitive and consumer-discretionary investments. Indeed, we may now be reaching the point where the focus shifts from buying the recovery to factoring in the potential risks to its continuation, such as labour, supply chains, and rising energy prices

The FTSE All-Share index has delivered a total return of around 13% year-to-date (YTD). A pro-growth, pro-recovery environment is not generally one in which healthcare outperforms, as it is not a cyclical sector. But the YTD total returns of the US and European healthcare indices are 11.6% and 10.5% respectively.

All is not as it seems

These impressive figures belie greater turbulence below the surface, however. Small- and mid-cap healthcare companies, especially biotechnology stocks, have fared poorly. The US Nasdaq Biotechnology index has appreciated only 3%. The US small- and mid-cap Russell 2000 healthcare index is down by 9% in 2021, and the widely followed XBI Biotech ETF has slipped by 12%. 

Why is this fast-growing, innovative sector struggling and how long might this go on for? In addition to the broader macroeconomic headwinds, three factors stand out for healthcare. Firstly, in the US the Democrats’ continuing push to append some sort of drug-price reform to the budget reconciliation process is dissuading generalist investors from increasing drug-related exposure. 

Secondly, the US Food and Drug Administration has become less predictable over the past nine months, prompting investors to discount any potentially significant upcoming approval decision. This will weigh more on early-stage companies than more mature ones with many approved products. 

Lastly, the US Federal Trade Commission has also become harder to anticipate, leading companies to fret that mergers and acquisitions (M&A) will become more time-consuming and distracting to management. An “M&A option” premium has long bolstered market sentiment towards small- and mid-cap healthcare companies, but it has now dwindled. 

The problems are in the price

None of these three problems looks likely to be solved soon. However, there comes a point when share prices have arguably discounted the obstacles and fallen to attractive entry points – especially for investors concerned about a worsening economic outlook. Two key themes for us are patients taking more responsibility for managing chronic conditions and the provision of care outside of hospitals and doctors’ surgeries. We like Option Care Health (Nasdaq: OPCH), a specialist in home-infusion therapies allowing people to avoid hospitals. 

We are also impressed by Tandem Diabetes Care (Nasdaq: TNDM), which offers “closed-loop” systems to manage insulin-dependent diabetes efficiently: the insulin pump communicates with the glucose monitor to adjust dosage levels automatically. Finally, we like biotechnology group, Sarepta Therapeutics (Nasdaq: SRPT), a gene-therapy pioneer developing solutions for rare diseases. It looks as though this technology may soon fulfil its promise.

Recommended

The hidden cost of employee share schemes
Investment strategy

The hidden cost of employee share schemes

Paying employees in shares comes at a cost to investors – but it isn’t always easy to see how much, says Stephen Clapham.
26 Sep 2022
Sterling crashes to its lowest since 1985 after mini-Budget
Currencies

Sterling crashes to its lowest since 1985 after mini-Budget

The pound has fallen hard and is heading towards parity with the US dollar. Saloni Sardana explains why, and what it means for the UK, for markets and…
23 Sep 2022
The pick of this year's best-performing investment trusts
Investment trusts

The pick of this year's best-performing investment trusts

Market conditions haven’t been easy, but these investment trusts have delivered strong growth, says David Stevenson.
23 Sep 2022
Earn 3.7% from the best savings accounts
Savings

Earn 3.7% from the best savings accounts

With inflation topping 10%, your savings won't keep pace with the rising cost of living. But you can at least slow the rate at which your money is los…
23 Sep 2022

Most Popular

Could gold be the basis for a new global currency?
Gold

Could gold be the basis for a new global currency?

Gold has always been the most reliable form of money. Now collaboration between China and Russia could lead to a new gold-backed means of exchange – g…
22 Sep 2022
Paypal, bitcoin, and the weaponisation of money
Bitcoin & crypto

Paypal, bitcoin, and the weaponisation of money

Recent events have shown how both business and governments can “weaponise” money and shut down dissent. What to do? Buy bitcoin, says Dominic Frisby.
22 Sep 2022
Why you should short this satellite broadband company
Trading

Why you should short this satellite broadband company

With an ill-considered business plan, satellite broadband company AST SpaceMobile is doomed to failure, says Matthew Partridge. Here's how to short th…
23 Sep 2022